Single wall nanotube constructs and uses thereof

Patent metadata

Field	Value
Publication number	US-10406236-B2
Application number	US-201715494974-A
Country	US
Kind code	B2
Filing date	Apr 24, 2017
Priority date	Jul 29, 2005
Publication date	Sep 10, 2019
Grant date	Sep 10, 2019

Abstract

The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

First claim

What is claimed is:

1. A method of treating a cancer in a subject, comprising:
administering a soluble single wall carbon nanotube (SWNT) construct having the structure SWNT-(DNA 1,2 -(cDNA 1 -peptide) m -(cDNA 2 -M*tetraazacyclododecane-1,4,7,10-tetra acetic acid (DOTA)) n ) x , such that cDNA 1 is linked to the peptide, cDNA 2 is linked to DOTA and DNA 1,2 is linked to the SWNT; and, wherein cDNA 1 and cDNA 2 independently are non-identical oligomers and DNA 1,2 is an oligomer with a sequence complementary to cDNA 1 and cDNA 2 ; and, wherein said DNA 1,2 is the sequence shown in SEQ ID NO: 1, said cDNA 1 is the sequence shown in SEQ ID NO: 2 and said cDNA 2 is the sequence shown in SEQ ID NO: 3; and, wherein said peptide is a targeting antibody or a targeting cyclic RGD or an NGR peptide ligand, M* is a radionuclide, x is 1 to 300; and m and n are independently 1 to 300; wherein, upon targeting cancer-associated cells with the peptide, said radionuclide M* has an anticancer effect against said cells thereby treating the cancer in the subject.

2. The method of claim 1 , wherein the targeting antibody is a therapeutic antibody.

3. The method of claim 2 , wherein the therapeutic antibody is rituximab, trastuzumab, or antinucleolin.

4. The method of claim 1 , wherein M* is actinium-225, astatine-211, technetium-99, lutetium-177, gallium-68, holmium-166, bismuth-212, bismuth-213, yttrium-90, copper-64, copper-67, samarium-117, samarium-153, iodine-123, iodine-124, iodine-125, or iodine-131.

5. The method of claim 1 , wherein said cancer associated cells are cancer cells or endothelial cells of the vasculature associated with the cancer.

Assignees

• Scheinberg David A
• Mcdevitt Michael R
• Antczak Christophe
• Chattopadhyay Debjit
• May Rena
• Njardarson Jon
• Phillips Mark Reid
• Sloan Kettering Inst Cancer Res

Inventors

• Scheinberg David A
• Mcdevitt Michael R
• Antczak Christophe
• Chattopadhyay Debjit
• May Rena
• Njardarson Jon
• Phillips Mark Reid

Classifications

• C01B32/176

  Cutting · CPC title

• A61K47/6925

  the form being a microcapsule, nanocapsule, microbubble or nanobubble · CPC title

• C01B32/174

  Derivatisation; Solubilisation; Dispersion in solvents · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• B82Y30/00

  Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title